Aptose Biosciences

Cancer Drugs

Luxeptinib 2 trials Clin1/Clin2 multiple blood cancers; APTO-253 Clin1 AML, MDS; APL-581 Clin0 blood cancers

Aptose Biosciences is developing first-in-class precision medicines to treat cancers with unmet clinical need. Aptose’s approach is to design products that provide single agent efficacy that can be combined with conventional anti-cancer therapies by simultaneously targeting key drivers of disease in cancer cells. The effect is to enhance the overall efficacy and preserve quality of life in cancer patients. Aptose currently has two clinical-stage investigational products for hematologic malignancies. This includes Luxeptinib, an oral, mutation-agnostic, dual lymphoid/myeloid kinome inhibitor for B-cell tumors and Tuspetinib, an oral, potent myeloid kinome inhibitor that is under development for patients with acute myeloid leukemia.